Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIFECTA-DARED: Pubertal Induction in Turner Syndrome
NCT07041814Phase 2Not yet recruiting
- Sponsor
- Hospital Canselor Tuanku Muhriz
- Start
- Feb 2026
- Primary completion
- Apr 2029
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of estradiol topical in Turner syndrome (TS) (2 arms), sponsored by Hospital Canselor Tuanku Muhriz. Primary endpoints: Proportions of Turner Syndrome with Satisfactory Breast Development (Tanner Breast Stage 3 and above) at 19 months, Median time to achieving Tanner Breast Stage 4 (B4) and above at 19 months and 2 more. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
estradiol topical
03
Conditions
Turner syndrome (TS)
Beyond the preview
Go deeper on NCT07041814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07041814.